This study aimed to compare the effect of 4 different intracanal medicaments on the push-out bond strength of two sealers (AH Plus and MTA Fillapex). 100 single-rooted extracted premolar teeth were divided into 5 groups, with 20 samples in each group, one group being the control group. After cleaning and shaping procedures, the canals were filled with 4 different medicaments: calcium hydroxide, tri-antibiotic paste (TAP), Metapex, or Chlorhexidine (2%) gel for 2 weeks. Following this, the medicaments were rinsed away, and the samples in those sub-groups were obturated with gutta-percha/AH Plus or MTA Fillapex sealers. After 2 weeks of incubation, a 2-mm-thick middle section from each root was evaluated to test push-out strength. The obtained data were tabulated, and appropriate statistical analysis was performed (two-way ANOVA and LSD test). When comparing the average values, the bond strength values of AH Plus were significantly higher than those of MTA Fillapex (p<0.05) in all medicament groups. Based on the findings, we concluded that AH Plus had comparatively higher bond strength than MTA Fillapex. We also observed that AH Plus had higher bond strength in the presence of calcium hydroxide, whereas MTA Fillapex in the presence of Chlorhexidine. A comparison of the push-out bond strength shows that irrespective of the root canal segment or the final irrigant used, AH Plus showed higher values among all groups. The limitation of the current study was that the effect of TAP on the bond strength of endodontic sealers was not negative.

Background: Metabolic syndrome is a set of metabolic disorders and is considered as a predictor of cardiovascular risks. The expression of several specific genes and the related protein products also show their significance in pathophysiology of Metabolic Syndrome. Secreted Frizzled Related Protein 4 is a product of expression of SFRP4 genes. SFRP4 has been linked with inflammatory responses quite similar to the responses as in metabolic syndrome pathogenesis. Aim: The current study aimed to assess the circulatory level of Secreted Frizzled Related Protein 4 among metabolic syndrome individuals. Method: Estimation of SFRP4 was done by ELISA technique by using Human SFRP4 ELISA kit (Make- Bioassay Technology Laboratory, Cat no- E2327Hu, Zeijhang, China). Results: Mean concentration of serum SFRP4 in Metabolic Syndrome subjects (2.06 ± 1.39 ng/ml) was significantly higher than the mean concentration of healthy controls (1.28 ± 1.29 ng/ml)  (p< 0.05 *). Conclusion: A significant correlation of serum SFRP4 level with Fasting blood glucose and HbA1c seen in the findings of this study puts on an extra contribution to consider this protein as a potential Biomarker for Type II Diabetes Mellitus.